<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03819972</url>
  </required_header>
  <id_info>
    <org_study_id>PROCAL-JW</org_study_id>
    <nct_id>NCT03819972</nct_id>
  </id_info>
  <brief_title>The Dose Response of Calcium Co-ingested With Protein on GLP-1 Concentrations</brief_title>
  <acronym>PROCAL</acronym>
  <official_title>The Dose Response of Milk Minerals High in Calcium With Protein on Plasma Glucagon-Like Peptide-1 Concentrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bath</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bath</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hormones that are produced by our stomach and intestines play a role in regulating our&#xD;
      appetite and health. One of the most important hormones is called GLP-1. The food we eat&#xD;
      influences the release of this hormone and evidence suggests that protein and calcium are key&#xD;
      nutrients that stimulate the secretion of GLP-1. We want to know if there is a dose related&#xD;
      response by increasing the amount of calcium ingested with a constant amount of protein on&#xD;
      the release of this hormone. We hypothesise that with increasing calcium dose we will see an&#xD;
      increase in GLP-1 concentrations in a curvilinear pattern. This may have benefits for&#xD;
      prescribing an optimal dose of calcium for weight maintenance and health.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent work at the University of Bath has shown that when ingested with 50 g whey protein&#xD;
      hydrolysate, Capolac® (milk minerals high in calcium) potently stimulates availability of the&#xD;
      important hormone glucagon-like peptide-1 (GLP-1). However, it is currently unknown as to&#xD;
      whether there is a dose dependent response to calcium co-ingestion with protein. Therefore we&#xD;
      aim to perform a study on the effect of co-ingesting different doses of Capolac® with 25 g&#xD;
      whey protein hydrolysate on GLP-1 availability. This project will help identify the calcium&#xD;
      dose required with a moderate amount of protein to optimise GLP-1 availability and also&#xD;
      provide insight into whether this may affect food intake and appetite.&#xD;
&#xD;
      Twenty metabolically healthy men and women, age 18-65 years, BMI between 25 and 34.9 kg/m2&#xD;
      will be recruited to participate in a randomised crossover study. Each participant will&#xD;
      undergo 4 trials. Each trial will last ~4 hours and will be separated by a minimum of 48h:&#xD;
&#xD;
        1. CONTROL - 25 g whey protein hydrolysate (227 mg of total calcium ingested)&#xD;
&#xD;
        2. DOSE 1 - 25 g whey protein hydrolysate + 3179 mg Capolac (984 mg of total calcium&#xD;
           ingested)&#xD;
&#xD;
        3. DOSE 2 - 25 g whey protein hydrolysate + 6363 mg Capolac (1742 mg of total calcium&#xD;
           ingested)&#xD;
&#xD;
        4. DOSE 3 - 25 g whey protein hydrolysate + 9547 mg Capolac (2500 mg of total calcium&#xD;
           ingested) Each of these drinks will also contain 500 mL of water and low calorie&#xD;
           sweetener (80 mg sucralose).&#xD;
&#xD;
      Participants will be asked to arrive to the laboratory between 08:00 and 9:00 am after not&#xD;
      eating for between 10-14 hours i.e. in a fasted state (water intake is permitted and&#xD;
      encouraged). Upon arrival at the laboratory a trained phlebotomist staff member will insert a&#xD;
      cannula (a small plastic tube) into a vein in the back of the hand. Participants will then be&#xD;
      given one of the four test drinks, which once ingested will initiate the trial. Just after&#xD;
      the ingestion of the test drink we will ask you to fill out a palatability scale.&#xD;
&#xD;
      Blood samples will be taken at baseline, and at 15, 30, 45, 60, 90, 120 and 180 minutes after&#xD;
      ingestion of the test drink. An appetite questionnaire will also be completed at baseline and&#xD;
      every 60 minutes after ingestion of the test drink to assess appetite sensations. After the&#xD;
      180-minute time point participants will be asked to consume a lunch meal until they are&#xD;
      comfortably full. Once satisfied with the lunch meal they will fill out the final appetite&#xD;
      questionnaire. The trial day will then be complete. Following study completion participants&#xD;
      will be asked to complete a restrained eating questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2019</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>There are 4 conditions where participants will ingest differing amounts of calcium in a randomised order</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participant will not be told which drink they will ingest until the end of the study.&#xD;
Individuals not collaborating on the study will randomise the drink order and make up the drinks so the investigator is blinded to which drink the particpant will ingest.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total plasma glucagon-like peptide-1 concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Blood sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Active plasma glucagon-like peptide-1 concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma NEFA concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma albumin concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective appetite</measure>
    <time_frame>4 hours</time_frame>
    <description>Visual appetite scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ad libitum food intake</measure>
    <time_frame>4 hours</time_frame>
    <description>lunch meal</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>GLP-1 Concentration</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will ingest a drink containing 25 g whey protein hydrolysate (227 mg of total calcium ingested)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will ingest a drink containing 25 g whey protein hydrolysate and 3179 mg Capolac (984 mg of total calcium ingested)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will ingest a drink containing 25 g whey protein hydrolysate and 6363 mg Capolac (1742 mg of total calcium ingested)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will ingest a drink containing 25 g whey protein hydrolysate and 9547 mg Capolac (2500 mg of total calcium ingested)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dose response of Capolac®</intervention_name>
    <description>Capolac® (milk minerals high in calcium) dose is manipulated</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index 25.0-34.9 kg∙m-2&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Able and willing to provide informed consent and safely comply with study procedures&#xD;
&#xD;
          -  Females to maintain record of regular menstrual cycle phase or contraceptive use&#xD;
&#xD;
          -  No anticipated changes in diet/physical activity during the study (e.g. holidays or&#xD;
             diet plans)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergies or adverse reactions to calcium or milk proteins.&#xD;
&#xD;
          -  Contradictions to a high intake of calcium e.g. history of kidney stones&#xD;
&#xD;
          -  Any reported condition or behaviour deemed either to pose undue personal risk to the&#xD;
             participant or introduce bias&#xD;
&#xD;
          -  Any diagnosed metabolic disease (e.g. type 1 or type 2 diabetes)&#xD;
&#xD;
          -  Any reported use of substances which may pose undue personal risk to the participants&#xD;
             or introduce bias into the experiment&#xD;
&#xD;
          -  Lifestyle not conforming to standard sleep-wake cycle (e.g. shift worker)&#xD;
&#xD;
          -  Any reported recent (&lt;6 months) change in body mass (± 3%)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department for Health, University of Bath</name>
      <address>
        <city>Bath</city>
        <state>Somerset</state>
        <zip>BA2 7AY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bath</investigator_affiliation>
    <investigator_full_name>Jonathan Watkins</investigator_full_name>
    <investigator_title>PhD Student</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

